LeMaitre Vascular Inc (LMAT) : Awm Investment Company reduced its stake in LeMaitre Vascular Inc by 13.64% during the most recent quarter end. The investment management company now holds a total of 836,614 shares of LeMaitre Vascular Inc which is valued at $19,317,417 after selling 132,146 shares in LeMaitre Vascular Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.LeMaitre Vascular Inc makes up approximately 3.94% of Awm Investment Company’s portfolio.
Other Hedge Funds, Including , Bogle Investment Management L P De added LMAT to its portfolio by purchasing 73,165 company shares during the most recent quarter which is valued at $1,689,380. LeMaitre Vascular Inc makes up approx 0.12% of Bogle Investment Management L P De’s portfolio. Citadel Advisors sold out all of its stake in LMAT during the most recent quarter. The investment firm sold 14,706 shares of LMAT which is valued $342,650.Blackrock Advisors boosted its stake in LMAT in the latest quarter, The investment management firm added 43,839 additional shares and now holds a total of 67,165 shares of LeMaitre Vascular Inc which is valued at $1,470,242.Tiaa Cref Investment Management boosted its stake in LMAT in the latest quarter, The investment management firm added 508 additional shares and now holds a total of 80,068 shares of LeMaitre Vascular Inc which is valued at $1,752,689. Greenleaf Trust added LMAT to its portfolio by purchasing 14,738 company shares during the most recent quarter which is valued at $289,160. LeMaitre Vascular Inc makes up approx 0.01% of Greenleaf Trust’s portfolio.
LeMaitre Vascular Inc opened for trading at $24.77 and hit $24.89 on the upside on Monday, eventually ending the session at $24.67, with a gain of 0.24% or 0.06 points. The heightened volatility saw the trading volume jump to 1,58,873 shares. Company has a market cap of $458 M.
On the company’s financial health, LeMaitre Vascular Inc reported $0.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Oct 26, 2016. Analyst had a consensus of $0.15. The company had revenue of $23.20 million for the quarter, compared to analysts expectations of $22.20 million. The company’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.
LeMaitre Vascular Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop manufacture and market medical devices and implants used primarily in the field of vascular surgery. The Company’s product lines include valvulotomes balloon catheters carotid shunts biologic patches biologic grafts radiopaque marking tape anastomotic clips remote endarterectomy devices laparoscopic cholecystectomy devices vascular grafts angioscopes and powered phlebectomy devices. The Company develops manufactures and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome the Pruitt F3 Carotid Shunt VascuTape Radiopaque Tape and the XenoSure biologic patch.